ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR
Update: 2025-09-04
Description
What role does mitochondrial dysfunction play in the pathogenesis of AMD? And could intervention change the course of early disease progression. David Lally, MD, shares results from the ReCLAIM-2 study, the phase 2 trial that assessed elamipretide (Stealth BioTherapeutics) in patients with non-central GA. What positive treatment effects were observed? And Ehsan Rahimy, MD, reviews findings from a retrospective analysis seeking to understand if continuous glucose monitoring could reduce the risk of NPDR progressing to more serious conditions. Listen in to learn what he and his colleagues found.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
